碘难治性甲状腺癌远处转移处理策略OA北大核心CSTPCD

The incidence of thyroid cancer has increased year by year,and the incidence-based mortality trends have increased slowly.Radioiodine therapy is one of the standard therapies for differentiated thyroid cancer with distant metastasis.If the metastasis has no response or poor response for radioiodine therapy,the patients could be identified as radioiodine-refractory differentiated thyroid cancer(RR-DTC),with a low possibility of benefiting from subsequent single 131I therapy.Some RR-DTC cases with distant metastasis progress rapidly,which is tough in clinical diagnosis and further treatment.In recent years,the deepening exploration of molecular biology technology in the field of thyroid cancer has promoted the application of precise diagnosis and treatment based on molecular features in this field.Based on these advancements,active surveillance with TSH suppression,surgical treatment,local treatment,targeted therapy,targeted combination therapy with 131I,targeted combination immunotherapy,and other comprehensive treatment measures can be used for the treatment of distant metastases in RR-DTC.PRRT guided by nuclear medical molecular imaging may provide new hope for RR-DTC patients who have failed targeted treatments.